In 2006 the EU Commission fined AstraZeneca €60 million for violating Article 82 of the EC Treaty for abusing pharmaceutical marketing authorization procedures and patent systems in seven Member States in order to prevent or delay entry by generic drug manufacturers. AstraZeneca was found to have engaged in behaviors sometimes called the “evergreening” of patents, by which companies control market access for both generic producers and for parallel traders.
Associate Professor Birthe Larsen, Department of Economics - CBS, will present research on the consequences of negative attitudes towards immigrants' welfare based on regional variation in negative attitudes towards immigrants to Sweden.